JXR (01951) announced plans to further develop a translational medicine platform primarily focused on female health, marking a strategic move to strengthen its presence in this specialized therapeutic area.
In other corporate actions, SUN.KING TECH (00580) is set to participate in establishing a joint venture to invest in high-performance TPU AI chip-related businesses, while 安井食品 (02648) has made an overseas investment by setting up an Indonesian joint venture and signing a shareholders' agreement.
福田实业 (00420)'s subsidiary intends to acquire an 81% stake in a Vietnamese company for US$27.945 million, and HBM HOLDINGS-B (02142)'s partner Solstice Oncology has completed a US$225 million Series A financing round and officially commenced operations.
中国能源建设 (03996)'s subsidiary has won the EPC general contracting bid for the Shaanxi Touzhaoping Power Plant Phase II 2×1000MW unit project, with a winning bid amount of 6.44326 billion yuan. Additionally, LEE'S PHARM (00950) has signed an exclusive licensing agreement with 1cBio to develop, manufacture, and commercialize OC-3 in mainland China and other regions.
医渡科技 (02158)'s subsidiary 医渡云 has won the bid for the Shanghai Pulmonary Hospital data platform domestic adaptation and upgrade project, while 灵宝黄金 (03330)'s subsidiary plans to acquire 50%-1 share of TABAR ISLANDS HOLDINGS PTY LTD for A$410 million plus corresponding royalty obligations.
英硅智能 (03696) reported that its leading AI-driven candidate drug Rentosertib has completed first patient enrollment in a Phase III clinical trial for idiopathic pulmonary fibrosis. Meanwhile, 恒瑞医药 (01276)'s marketing authorization application for Ruiptatide injection has been accepted by the National Medical Products Administration.
BRAINAURORA-B (06681) has published its research findings on pediatric cognitive digital therapeutic dosing in BMC Medicine.
On the earnings front, 百本医护 (02293) issued a profit warning, expecting annual net profit attributable to shareholders of approximately HK$6-7 million, representing a year-on-year decrease. 德康农牧 (02419) reported commercial hog sales revenue of 10.740 billion yuan for the first eight months, while 江南布衣 (03306) released its annual results with shareholder net profit of 997 million yuan, up 11.7% year-on-year.